339 related articles for article (PubMed ID: 33090921)
1. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study.
Childress AC; Brams MN; Cutler AJ; Donnelly GAE; Bhaskar S
J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):580-589. PubMed ID: 33090921
[No Abstract] [Full Text] [Related]
2. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D
J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder.
Kollins SH; Braeckman R; Guenther S; Barrett AC; Mickle TC; Oh C; Marraffino A; Cutler AJ; Brams MN
J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):597-609. PubMed ID: 34714120
[No Abstract] [Full Text] [Related]
5. Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Kando JC; King TR; Pardo A; Herman BK
J Child Adolesc Psychopharmacol; 2019 Feb; 29(1):2-8. PubMed ID: 30575407
[TBL] [Abstract][Full Text] [Related]
6. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.
Wigal SB; Childress AC; Belden HW; Berry SA
J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):3-10. PubMed ID: 23289899
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.
Childress AC; Cutler AJ; Marraffino A; McDonnell MA; Turnbow JM; Brams M; DeSousa NJ; Incledon B; Sallee FR; Wigal SB
J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):2-14. PubMed ID: 31464511
[No Abstract] [Full Text] [Related]
8. Efficacy and Safety of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Wigal SB; Brams MN; Turnbow JM; Pincus Y; Belden HW; Berry SA
J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):306-313. PubMed ID: 29211967
[TBL] [Abstract][Full Text] [Related]
9. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.
Wigal SB; Greenhill LL; Nordbrock E; Connor DF; Kollins SH; Adjei A; Childress A; Stehli A; Kupper RJ
J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):562-9. PubMed ID: 25470572
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.
Silva RR; Muniz R; Pestreich L; Childress A; Brams M; Lopez FA; Wang J
J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):239-51. PubMed ID: 16768632
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.
Brams M; Muniz R; Childress A; Giblin J; Mao A; Turnbow J; Borrello M; McCague K; Lopez FA; Silva R
CNS Drugs; 2008; 22(8):693-704. PubMed ID: 18601306
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.
Childress AC; Brams M; Cutler AJ; Kollins SH; Northcutt J; Padilla A; Turnbow JM
J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):402-14. PubMed ID: 25692608
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension.
Weiss MD; Cutler AJ; Kollins SH; Donnelly GAE
J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):610-622. PubMed ID: 34637343
[No Abstract] [Full Text] [Related]
14. Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.
Silva RR; Brams M; McCague K; Pestreich L; Muniz R
Clin Neuropharmacol; 2013; 36(4):117-21. PubMed ID: 23860345
[TBL] [Abstract][Full Text] [Related]
15. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Kollins SH; Foehl HC; Newcorn JH; Mattingly G; Kupper RJ; Adjei AL
J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):58-68. PubMed ID: 32125903
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
Muniz R; Brams M; Mao A; McCague K; Pestreich L; Silva R
J Child Adolesc Psychopharmacol; 2008 Jun; 18(3):248-56. PubMed ID: 18582179
[TBL] [Abstract][Full Text] [Related]
17. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.
Silva R; Muniz R; McCague K; Childress A; Brams M; Mao A
Psychopharmacol Bull; 2008; 41(1):19-33. PubMed ID: 18362868
[TBL] [Abstract][Full Text] [Related]
18. Gender Effects in the Efficacy of Racemic Amphetamine Sulfate in Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Newcorn JH; Cutler AJ
Adv Ther; 2019 Jun; 36(6):1370-1387. PubMed ID: 30972657
[TBL] [Abstract][Full Text] [Related]
19. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
[TBL] [Abstract][Full Text] [Related]
20. Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adult Laboratory Classroom Study of the Efficacy and Safety of PRC-063 (Extended-Release Methylphenidate) for the Treatment of ADHD.
Childress A; Cutler AJ; Marraffino AH; Bhaskar S; Donnelly G
J Atten Disord; 2022 Apr; 26(6):857-869. PubMed ID: 34189995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
